Organogenesis Hldgs Q4 2023 GAAP EPS $0.010, Inline, Sales $99.651M Miss $109.050M Estimate
Portfolio Pulse from Benzinga Newsdesk
Organogenesis Holdings (ORGO) reported Q4 2023 earnings of $0.010 per share, meeting analyst estimates. However, their quarterly sales of $99.651 million fell short of the expected $109.050 million, marking an 8.62% miss and a 13.73% decrease from the previous year.
February 29, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Organogenesis Holdings reported in-line Q4 2023 earnings but missed revenue estimates, with a significant year-over-year decrease.
Missing revenue estimates and reporting a significant decrease in sales year-over-year are likely to negatively impact investor sentiment and the stock price in the short term. The in-line earnings per share may not be sufficient to offset concerns about declining sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100